Citadel Advisors’s Cascadian Therapeutics, Inc. CASC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q4 | – | Sell |
-1,667
| Closed | -$16K | – | 8239 |
|
|
2016
Q3 | $16K | Buy |
+1,667
| New | +$11.8K | ﹤0.01% | 7107 |
|
|
2016
Q2 | – | Sell |
-2,833
| Closed | -$22K | – | 7778 |
|
|
2016
Q1 | $22K | Buy |
2,833
+2,333
| +467% | +$18K | ﹤0.01% | 6442 |
|
|
2015
Q4 | $7K | Sell |
500
-1,067
| -68% | -$18.4K | ﹤0.01% | 8385 |
|
|
2015
Q3 | $26K | Sell |
1,567
-5,700
| -78% | -$117K | ﹤0.01% | 8024 |
|
|
2015
Q2 | $163K | Buy |
+7,267
| New | +$115K | ﹤0.01% | 6573 |
|
|
2015
Q1 | – | Sell |
-83
| Closed | -$1K | – | 9054 |
|
|
2014
Q4 | $1K | Buy |
+83
| New | +$901 | ﹤0.01% | 8434 |
|
|
2014
Q2 | – | Sell |
-733
| Closed | -$13K | – | 8537 |
|
|
2014
Q1 | $13K | Sell |
733
-100
| -12% | -$1.64K | ﹤0.01% | 7438 |
|
|
2013
Q4 | $9K | Sell |
833
-317
| -28% | -$3.54K | ﹤0.01% | 6739 |
|
|
2013
Q3 | $14K | Buy |
1,150
+700
| +156% | +$7.37K | ﹤0.01% | 6380 |
|
|
2013
Q2 | $4K | Buy |
+450
| New | +$5.78K | ﹤0.01% | 6368 |
|
Citadel Advisors's CASC Position: Q1 2018 in Review
Citadel Advisors sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 10,792 shares — an estimated $40K sold.
Citadel Advisors first reported a position in CASC in Q2 2013 and held it in 15 quarters. The position peaked at $523K in Q2 2015. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.
- Citadel Advisors reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
- Citadel Advisors sold 10,792 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $40K.
- Citadel Advisors first reported a position in Cascadian Therapeutics, Inc. in Q2 2013 and held it in 15 quarters.
- Citadel Advisors's Cascadian Therapeutics, Inc. position peaked at $523K in Q2 2015.
- 1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.
Based on Citadel Advisors's 13F filing for Q1 2018, filed 11 May 2018.